📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-20 19:27
670 analysed today
670
Today
135,957
All-time analysed
40,377
Positive
6,310
Negative
81,360
Neutral
7,842
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
5 announcements match the current filters (relevance ≥ 5).
NCLT Approves Scheme of Amalgamation of Vitanosh Ingredients with Lactose India
Lactose (India) Limited has received the certified true copy of the Hon'ble NCLT Ahmedabad Bench order dated August 5, 2026, sanctioning the Scheme of Amalgamation with Vitanosh Ingredients Private Limited. The certified order copy was received by the company on August 20, 2026. The scheme will become effective upon subsequent statutory filings, after which financial and operational integration details will take effect.
Confidence: HIGH
What changedThe Scheme of Amalgamation of Vitanosh Ingredients Private Limited with Lactose (India) Limited has received formal sanction from NCLT Ahmedabad.
Why it mattersFormalizes the consolidation of business operations, potential synergies, and asset integration between Vitanosh Ingredients and Lactose India.
NCLT Sanction Order Date: 05th August 2026Certified Copy Received Date: 20th August 2026Market Cap context: ₹125 Cr
📅 Short termClearance from NCLT removes legal overhang on the restructuring; the stock may react positively to the formal regulatory approval.
📈 Long termPost-merger integration could support manufacturing scale, operational synergies, and supply-chain efficiency depending on the operational profile of the transferor company.
⚠ Risk flags
- Post-merger integration risks
- Share capital dilution details post-amalgamation not specified in filing
Key Highlights
NCLT Ahmedabad Bench sanctioned the Scheme of Amalgamation vide order dated August 5, 2026
Certified true copy of the NCLT order received by the company on August 20, 2026
Scheme involves the merger of Vitanosh Ingredients Private Limited into Lactose (India) Limited under Sections 230-232 of the Companies Act, 2013
👀 What to Watch
Track the subsequent announcement regarding the effective date of the scheme and any share swap/issuance details or combined balance sheet updates.
NCLT Approves Scheme of Amalgamation of Vitanosh Ingredients with Lactose India
Lactose India Ltd has received the certified true copy of the NCLT Ahmedabad Bench order sanctioning the Scheme of Amalgamation with Vitanosh Ingredients Private Limited. The order, dated August 5, 2026, was received by the company on August 20, 2026. The merger brings the transferor entity into Lactose India (market cap of ₹125 crore, TTM revenue ₹171 crore), with formal scheme effectiveness disclosures to follow.
Confidence: HIGH
What changedNCLT Ahmedabad Bench has sanctioned the Scheme of Amalgamation between Vitanosh Ingredients Private Limited and Lactose India Limited, clearing the primary legal hurdle for the merger.
Why it mattersConsolidates operations and corporate structures under Lactose India, potentially driving operational synergies for its pharma excipient and API manufacturing business.
NCLT Order Date: 05th August 2026Order Receipt Date: 20th August 2026Company Market Cap: ₹125 CrTTM Revenue: ₹171 Cr
📅 Short termClearance of regulatory approval removes legal overhang; watch for filing of the certified order with the Registrar of Companies (RoC) to make the scheme effective.
📈 Long termPost-merger integration will determine operational and financial synergies as the company scales capacity in lactose and lactulose.
⚠ Risk flags
- Financial details and swap ratio/share dilution terms of Vitanosh Ingredients are not detailed in the intimation letter
- Post-merger execution and integration risks
Key Highlights
Hon'ble NCLT Ahmedabad Bench approved the Scheme of Amalgamation vide order dated August 5, 2026
Certified true copy of the NCLT order received by the company on August 20, 2026
Scheme involves the amalgamation of Vitanosh Ingredients Private Limited into Lactose (India) Limited
Effectiveness of the scheme and subsequent corporate filings will be intimated in due course
👀 What to Watch
Track subsequent filings regarding the effective date of the amalgamation, share allotment/swap details (if any), and post-merger integrated financials.
58% YoY Profit Growth in Q1; ₹6.52 Cr Warrants Forfeited
Lactose India reported a strong start to FY27 with Q1 revenue growing 18.7% YoY to ₹46.97 Cr. Net Profit surged 58% YoY to ₹2.37 Cr, driven by improved operational performance as expenses grew slower than revenue. A significant balance sheet event occurred as 15,00,000 warrants were forfeited due to non-payment of the remaining 75% exercise price, resulting in ₹6.525 Cr being transferred to Capital Reserves. The company also confirmed that its merger with Vitanosh Ingredients is currently awaiting final SEBI and NCLT approvals.
Confidence: HIGH
What changedThe company delivered strong double-digit growth in both top and bottom lines for Q1 FY27 and strengthened its capital reserves through warrant forfeiture.
Why it mattersThe strong profit growth indicates improving manufacturing efficiency or a better product mix. The warrant forfeiture, while providing 'free' capital to the company, also indicates that the market price (₹100.2) remained significantly below the warrant exercise price (₹174), leading to the lapse.
Q1 Revenue vs TTM Revenue: 28.8%Net Profit Growth (YoY): 58%Warrant Forfeiture Amount: ₹6.525 CrRevenue from Operations: ₹46.97 CrEPS (Basic): ₹1.88
📅 Short termThe stock is likely to react positively to the strong earnings growth and the non-dilutive addition to capital reserves.
📈 Long termLong-term value depends on the successful integration of Vitanosh Ingredients and the execution of the 20,000 MTPA capacity expansion to capture the 20% projected growth rate.
⚠ Risk flags
- High Debt-to-Equity ratio (0.95)
- Merger execution and regulatory approval risks
- Warrant holders' lack of participation suggests valuation misalignment at higher price points
Key Highlights
Revenue from operations increased 18.7% YoY to ₹46.97 Cr from ₹39.58 Cr.
Net Profit after tax grew 58% YoY to ₹2.37 Cr compared to ₹1.50 Cr in the previous year's quarter.
Forfeited ₹6.525 Cr in upfront warrant payments after holders failed to pay the balance 75% by the June 5, 2026 deadline.
Earnings Per Share (EPS) improved to ₹1.88 from ₹1.19 in the year-ago period.
Total Comprehensive Income for the quarter stood at ₹2.37 Cr vs ₹1.50 Cr YoY.
👀 What to Watch
Investors should monitor the timeline for the Vitanosh Ingredients merger and track the progress of the planned capacity expansion to 20,000 MTPA for Lactose, which is key to sustaining this growth rate.
58% PAT Growth in Q1 FY27; Rs 6.52 Cr Warrant Forfeiture Boosts Capital Reserve
Lactose India reported a strong Q1 FY27 with revenue growing 18.7% YoY to Rs 46.97 Cr and Net Profit increasing 58% to Rs 2.37 Cr. A significant non-operational event occurred as the company forfeited Rs 6.525 Cr (25% upfront payment) from 15 lakh unexercised warrants, transferring the amount to Capital Reserve. The warrant exercise price was Rs 174, significantly above the current market price of Rs 102, explaining the non-exercise. Additionally, the merger with Vitanosh Ingredients is progressing, having received shareholder approval and now awaiting NCLT/SEBI clearance.
Confidence: HIGH
What changedLactose India delivered strong double-digit earnings growth and strengthened its balance sheet through a Rs 6.52 Cr warrant forfeiture.
Why it mattersThe earnings growth validates the company's 20% growth strategy, while the warrant forfeiture provides a non-dilutive boost to capital reserves, although it highlights that the market price is currently well below previous internal valuation benchmarks (Rs 174).
Q1 Revenue: Rs 46.97 CrQ1 PAT Growth (YoY): 58%Warrant Forfeiture Amount: Rs 6.525 CrForfeiture vs Net Worth: 10.03%Warrant Exercise Price: Rs 174
📅 Short termThe stock may react positively to the strong bottom-line growth and the addition to capital reserves, though the warrant forfeiture confirms that the Rs 174 price level is not currently supported by warrant holders.
📈 Long termStructural growth depends on the successful integration of Vitanosh Ingredients and the execution of the capacity expansion in the specialized lactose and lactulose segments.
⚠ Risk flags
- Warrant holders' refusal to exercise at Rs 174 indicates a valuation gap
- Regulatory delays in the pending merger
- High debt-to-equity ratio of 0.95
Key Highlights
Revenue from operations increased 18.7% YoY to Rs 46.97 Cr in Q1 FY27.
Net Profit surged 58% YoY to Rs 2.37 Cr from Rs 1.50 Cr in the previous year's quarter.
Forfeited Rs 6.525 Cr from 15,00,000 unexercised warrants, representing ~10% of the company's net worth.
Basic EPS improved to Rs 1.88 for the quarter, up from Rs 1.19 in Q1 FY26.
Merger with Vitanosh Ingredients Private Limited is pending final SEBI and NCLT approvals.
👀 What to Watch
Investors should monitor the timeline for the Vitanosh Ingredients merger and the company's progress in doubling Lactose capacity to 20,000 MTPA to sustain this growth momentum.
₹90 Crore Bank Facilities Rated; CRISIL Reaffirms BBB-/Stable for Lactose India
CRISIL Ratings has reaffirmed its 'CRISIL BBB-/Stable' rating for the bank facilities of Lactose India Ltd. Notably, the total rated bank loan facilities have been enhanced by 50%, increasing from ₹60 crore to ₹90 crore. This enhancement includes a new ₹30 crore term loan from Bank of Baroda and ₹60 crore in cash credit limits across two banks. The stable outlook reflects the agency's expectation of steady operational performance and timely debt servicing.
Confidence: HIGH
What changedThe company's rated credit limit was increased by ₹30 crore (a 50% expansion in rated debt capacity) while maintaining its existing credit rating grade.
Why it mattersThe enhancement of bank facilities suggests the company is securing additional capital, likely for expansion or working capital needs, while maintaining an investment-grade credit profile.
Total Rated Facilities: ₹90 crorePrevious Rated Facilities: ₹60 croreEnhancement in Facilities: ₹30 croreTerm Loan Amount: ₹30 croreTotal Cash Credit Limit: ₹60 crore
📅 Short termThe reaffirmation of the credit rating provides immediate comfort regarding the company's financial stability and its ability to access higher credit limits.
📈 Long termThe 50% increase in rated debt capacity indicates a potential growth phase; the long-term impact depends on the company's ability to generate returns from this additional capital.
⚠ Risk flags
- Increased debt servicing obligations from the new ₹30 crore term loan
- Interest rate sensitivity on the total ₹90 crore facility
Key Highlights
Total rated bank loan facilities increased to ₹90 crore from the previous ₹60 crore.
Long-term rating reaffirmed at 'CRISIL BBB-/Stable' with a stable outlook.
New Term Loan of ₹30 crore sanctioned by Bank of Baroda for long-term requirements.
Cash credit facilities maintained at ₹60 crore, split between Bank of Baroda (₹35 cr) and YES Bank (₹25 cr).
The rating letter remains valid for use until March 31, 2027.
👀 What to Watch
Investors should monitor the company's upcoming quarterly results to see how the enhanced ₹30 crore debt facility is being utilized for growth and its impact on interest coverage ratios.
